Sodium‐glucose cotransporter‐2 inhibitors and kidney outcomes in real‐world type 2 diabetes populations: A systematic review and meta‐analysis of observational studies
Diabetes, Obesity and Metabolism · 2023
DOI: 10.1111/dom.15111 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Anna K Forbes und 7 weiteren Autor:innen. Beteiligte Einrichtung: Renal Services, Epsom & St. Helier University Hospitals NHS Trust, London, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Renal Insufficiency. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 58 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
To conduct a systematic review of observational studies to explore the real‐world kidney benefits of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors in a large and diverse population of adults with type 2 diabetes (T2D). Materials and Methods We searched MEDLINE, EMBASE and Web of Science for observational studies that investigated kidney disease progression in adults with T2D treated with SGLT2 inhibitors compared to other glucose‐lowering therapies. Studies published from database inception to July 2022 were independently reviewed by two authors and evaluated using the Risk of Bias in Non‐randomized Studies of Interventions (ROBINS‐I) tool. A random‐effects meta‐analysis was performed on studies with comparable outcome data, reported as hazard ratios (HRs) with 95% confidence intervals (CIs).
Results
We identified 34 studies performed across 15 countries with a total population of 1 494 373 for inclusion. In the meta‐analysis of 20 studies, SGLT2 inhibitors were associated with a 46% lower risk of kidney failure events compared with other glucose‐lowering drugs (HR 0.54, 95% CI 0.47–0.63). This finding was consistent across multiple sensitivity analyses and was independent of baseline estimated glomerular filtration rate (eGFR) or albuminuria status. SGLT2 inhibitors were associated with a lower risk of kidney failure when compared with dipeptidyl peptidase‐4 inhibitors and a combination of other glucose‐lowering drug classes (HR 0.50, 95% CI 0.38–0.67 and HR 0.51, 95% CI 0.44–0.59, respectively). However, when compared to glucagon‐like peptide 1 receptor agonists there was no statistically significant difference in the risk of kidney failure (HR 0.93, 95% CI 0.80–1.09).
Conclusions
The reno‐protective benefits of SGLT2 inhibitors apply to a broad population of adults with T2D treated in routine clinical practice, including those at lower risk of kidney events with normal eGFR and without albuminuria. These findings support the early use of SGLT2 inhibitors in T2D for preservation of kidney health.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Renal Services, Epsom & St. Helier University Hospitals NHS Trust, London, UK.
- Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
- Renal & Transplantation Unit, St George's University Hospitals NHS Foundation Trust, London, UK.
ORCID-Profile: Debasish Banerjee, Simon de Lusignan, Pauline A Swift
Zitieren
APA
Forbes, A. K., Suckling, R. J., Hinton, W., Feher, M. D., Banerjee, D., Cole, N. I., de Lusignan, S., & Swift, P. A. (2023). Sodium‐glucose cotransporter‐2 inhibitors and kidney outcomes in real‐world type 2 diabetes populations: A systematic review and meta‐analysis of observational studies. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15111
Vancouver
Forbes AK, Suckling RJ, Hinton W, Feher MD, Banerjee D, Cole NI, et al. Sodium‐glucose cotransporter‐2 inhibitors and kidney outcomes in real‐world type 2 diabetes populations: A systematic review and meta‐analysis of observational studies. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.15111
BibTeX
@article{Forbes2023,
author = {Forbes, Anna K and Suckling, Rebecca J and Hinton, William and Feher, Michael D and Banerjee, Debasish and Cole, Nicholas I and de Lusignan, Simon and Swift, Pauline A},
title = {Sodium‐glucose cotransporter‐2 inhibitors and kidney outcomes in real‐world type 2 diabetes populations: A systematic review and meta‐analysis of observational studies},
journal = {Diabetes, Obesity and Metabolism},
year = {2023},
doi = {10.1111/dom.15111}
}
EUVIMED